Literature DB >> 11113602

5-Lipoxygenase and cyclooxygenase mRNA expression in rat hippocampus:early response to glutamate receptor activation by kainate.

H Manev1, T Uz, T Qu.   

Abstract

Recent research has identified in central nervous system neurons the expression of two enzymes from the inflammatory pathway of the metabolism of arachidonic acid, the 5-lipoxygenase (5LOX) and the cyclooxygenase-2 (COX2). Expression of both enzymes appears to be upregulated during aging; upregulated 5LOX/COX2 expression in neurons may be responsible for the increased neuronal vulnerability to degeneration. Involvement of the excitatory neurotransmitter glutamate in aging-associated neurodegeneration has also been suggested. Stimulation of glutamate receptors by kainic acid (kainate) has been shown independently to affect the brain expression of 5LOX or COX2. Using a quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay to measure the contents of mRNAs we found 3h after kainate injection (intraperitoneally; 10 mg/kg) increased mRNA levels of 5LOX and COX2, but not that of COX1 in the hippocampus of rats. Pretreatment with the COX2 inhibitor NS-398 (9 mg/kg, 1h prior to kainate) inhibited the kainate-stimulated increase of 5LOX and COX2 mRNA levels. Our results indicate that hippocampal expression of both 5LOX and COX2 increases rather promptly when glutamate receptors are stimulated by kainate. The mechanism of how NS-398 inhibits this action of kainate should be further investigated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113602     DOI: 10.1016/s0531-5565(00)00152-2

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  8 in total

1.  Inflammation after stroke: mechanisms and therapeutic approaches.

Authors:  Muzamil Ahmad; Steven H Graham
Journal:  Transl Stroke Res       Date:  2010-06       Impact factor: 6.829

2.  A dual inhibitor of cyclooxygenase and 5-lipoxygenase protects against kainic acid-induced brain injury.

Authors:  Letteria Minutoli; Herbert Marini; Mariagrazia Rinaldi; Alessandra Bitto; Natasha Irrera; Gabriele Pizzino; Giovanni Pallio; Margherita Calò; Elena Bianca Adamo; Vincenzo Trichilo; Monica Interdonato; Federica Galfo; Francesco Squadrito; Domenica Altavilla
Journal:  Neuromolecular Med       Date:  2015-04-19       Impact factor: 3.843

3.  Co-administration of 3-Acetyl-11-Keto-Beta-Boswellic Acid Potentiates the Protective Effect of Celecoxib in Lipopolysaccharide-Induced Cognitive Impairment in Mice: Possible Implication of Anti-inflammatory and Antiglutamatergic Pathways.

Authors:  Aya Shoukry Sayed; Nesrine Salah El Dine El Sayed
Journal:  J Mol Neurosci       Date:  2016-03-16       Impact factor: 3.444

Review 4.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

5.  Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability.

Authors:  V P Chou; T R Holman; A B Manning-Bog
Journal:  Neuroscience       Date:  2012-10-16       Impact factor: 3.590

6.  Hippocampal neuronal cyclooxygenase-2 downstream signaling imbalance in a rat model of chronic aluminium gluconate administration.

Authors:  Hong Wang; Mengliang Ye; Lijuan Yu; Jianfeng Wang; Yuanxin Guo; Wenjuan Lei; Junqing Yang
Journal:  Behav Brain Funct       Date:  2015-02-18       Impact factor: 3.759

Review 7.  Kainic Acid-Induced Excitotoxicity Experimental Model: Protective Merits of Natural Products and Plant Extracts.

Authors:  Nur Shafika Mohd Sairazi; K N S Sirajudeen; Mohd Asnizam Asari; Mustapha Muzaimi; Swamy Mummedy; Siti Amrah Sulaiman
Journal:  Evid Based Complement Alternat Med       Date:  2015-12-17       Impact factor: 2.629

8.  Tualang Honey Reduced Neuroinflammation and Caspase-3 Activity in Rat Brain after Kainic Acid-Induced Status Epilepticus.

Authors:  Nur Shafika Mohd Sairazi; Kuttulebbai N S Sirajudeen; Mustapha Muzaimi; Swamy Mummedy; Mohd Asnizam Asari; Siti Amrah Sulaiman
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-15       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.